Objectives: Evaluate the prevalence and costs of selected comorbidities using a systematic approach.
Background
• GERD is a disease that affects employees and their employers.
• A number of comorbid conditions have been identified in persons with GERD, including:
• Asthma 1 and other respiratory diseases, 2 • Non-cardiac chest pain, [3] [4] 
and • Central Nervous System (CNS) Conditions
such as depression and anxiety. 5 • Comorbidity in GERD may be higher than expected for certain conditions, but comprehensive evaluations have not been undertaken to assess which GI and non-GI comorbid diseases are truly increased in GERD.
• Little is known about the cost of comorbid conditions associated with GERD in the community.
Objective
• To compare the prevalence and costs of selected comorbidites among employees with and without GERD using objectively defined disease categories.
Methods
• A retrospective analysis was performed using data from the Human Capital Management Services Research Reference Database (HCMS RRDb) of approximately 300,000 employees using 2001-2005 ad judicated claims and demographic data from employer records.
• International Classification of Diseases, Ninth Revision (ICD9) codes listed in Table 1 were used to identify employees with a primary, secondary, or tertiary diagnosis of GERD. • For each GERD subject 10 control patients were matched using logistic regression and propensity scores from demographic differences and region. Control patients were required to not have any of the GERD ICD9s.
• The index date for each employee with GERD was the first date of service associated with the disease. For controls, the index date was the average index date of subjects with GERD.
• All subjects needed to be continuously employed and eligible for health benefits for at least 1 year after their index date.
• All cost data were inflated to constant 2005 United States dollars.
• All claims were assigned to the 261 specific Agency for Healthcare Research and Quality (AHRQ) 6 categories based on the ICD9 codes on the claims, during the year following the index date.
• Mean costs were calculated over the entire cohort.
• Prevalence rates were based on persons within the cohort with claims for each category.
• Anonymity of person-level data was maintained according to the Health Insurance Portability and Accountability Act [HIPAA] guidelines.
Data Analysis
• Means and standard errors of demographic data were compared using t-tests for continuous variables and chi-square (x 2 ) tests for discrete variables.
• Prevalence comparisons used z-scores of log odds ratios (Woolf method), and the average cost comparisons used Sattherthwaite t-tests.
• Differences were considered significant when P≤0.05.
Results
• Data were available for 11,653 GERD and 116,530 matched controls ( Table 2) . 
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• Using the 261 AHRQ categories, the study identified:
• 204 categories with prevalence differences (197 categories more prevalent for the GERD cohort) • 152 categories with cost differences (145 categories more costly for the GERD cohort)
• All prevalences and costs of comorbidities reported in Table 3 are higher in the GERD cohort compared to controls (P<0.05) with the incremental differences shown in Figure 1 . All costs and prevalences significantly different between cohorts (P<0.05). 
Conclusions
• Patients with GERD have more prevalent comorbid conditions than subjects without GERD (75% of the 261 categories).
• From an insurer's perspective, this increased burden for GERD sufferers is also associated with higher costs.
• Patients with GERD have more costly comorbid conditions than subjects without GERD (56% of the 261 categories).
• Further research is needed to determine the relationship between GERD and the co-morbid conditions.
• This study population was composed of employed individuals: comorbidities might be different in other populations.
